This venture player is plotting $200M in new biotech investing — and they’re doubling down on a startup-rich strategy
Eight years ago, the partners at Hatteras Venture Partners reserved 20% of their fund for seed-stage plays. The impact of sequencing was spreading, driving a trend toward more targeted drugs. And out of that initiative came G1 Therapeutics $GTHX and a number of other biotechs that have continued down their own paths.
“I think we were probably ahead of our time when we launched that,” says Clay Thorp, Hatteras co-founder and GP. “We’re really pleased with the resurgence in seed and early-stage companies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
